Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margi

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperfo

Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript

Caris Life Sciences,?Inc. (CAI) reported break-even quarterly earnings per share versus the Zacks Co

Caris Life Sciences NASDAQ: CAI reported record clinical volume and raised its full-year revenue out

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&

Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $

Revenue growth of 45% driven by strong performance in molecular profiling services, including approx

Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implyin

IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio c

This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway m

IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-c

Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithms

ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewi

ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it ha

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and

IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-c

Caris Life Sciences is rated a buy, combining 79% Q1 2026 revenue growth, 65%+ gross margins, and po

Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-genera

IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Comp

A selloff in high-flying chipmakers split Wall Street on Thursday, with Broadcom Inc. (NASDAQ:AVGO)‘

Calgary, Alberta--(Newsfile Corp. - May 28, 2026) - Capitan Investment Ltd. (TSXV: CAI) (the "Corpor

Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was cor

ALLENTOWN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, with more than 40 year

Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, s

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical

Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the tim

The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved target

Citigroup analyst Patrick Donnelly maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowe

Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and

JP Morgan analyst Casey Woodring maintains Caris Life Sciences (NASDAQ:CAI) with a Overweight and

BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the pr

Caris Life Sciences (NASDAQ:CAI) affirms FY2026 sales outlook from $1.000 billion-$1.020 billion to

Caris Life Sciences (NASDAQ:CAI) reported quarterly sales of $216.174 million which beat the analyst

Caris Life Sciences® (NASDAQ:CAI), a leading, patient‑centric, next‑generation AI TechBio company an

Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patien

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

Jefferies analyst Tycho Peterson initiates coverage on Caris Life Sciences (NASDAQ:CAI) with a Bu

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperfo

Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid mal

Caris Life Sciences stock surges on positive Achieve 1 cancer test data. See key CAI levels and stud

Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company an

Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and

Caris AI Insights are proprietary and only available to Caris Life Sciences customersIRVING, Texas,

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperfo

Baird analyst Catherine Schulte maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and